| 초록 |
There are several problems with the medications available to treat rheumatoid arthritis (RA); short half-life, and drug toxicity ext. A study of formulations that can continuously release the drug is being required. Intra-articular injection has been suggested as a effective treatment of RA. So we have developed the effective RA drug carrier via hyaluronic acid (HA), which has a high bioavailability. The crosslinking agent was introduced into HA to improve the physical properties of the HA hydrogel and control the pore size of HA hydrogel for continuous drug release. We conducted cell viability and inflammation test. We confirmed the local release of NIR from the depot injected into the articular joint over an extended period. The effect of HA hydrogel as a RA drug depot was evaluated in vivo experiments over 1, 3, 6 weeks. Collectively, these results indicated the hydrogel that we developed induced sustained drug release and allowed to result in enhanced RA repair. |
